<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(2)</volume><submitter>Sinclair G</submitter><pubmed_abstract>Newborn screening for Cystic Fibrosis has been implemented in most programs worldwide, but the approach used varies, including combinations of immunoreactive trypsinogen (IRT) and CFTR mutation analysis on one or more specimens. The British Columbia (BC) newborn screening program tests ~45,000 infants per year in BC and the Yukon Territory, covering almost 1.5 million km&lt;sup>2&lt;/sup> in western Canada. CF screening was initiated using an IRT-DNA-IRT approach with a second bloodspot card at 21 days of age for all CFTR mutation heterozygotes and any non-carriers in the top 0.1% for IRT. This second IRT was implemented to avoid sweat testing of infants without persistent hypertrypsinemia, reducing the burden of travel for families. Over nine years (2010-2018), 401,977 infants were screened and</pubmed_abstract><journal>International journal of neonatal screening</journal><pagination>46</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7423010</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia.</pubmed_title><pmcid>PMC7423010</pmcid><pubmed_authors>Nelson TN</pubmed_authors><pubmed_authors>Chilvers M</pubmed_authors><pubmed_authors>Schellenberg A</pubmed_authors><pubmed_authors>McMahon V</pubmed_authors><pubmed_authors>Vallance H</pubmed_authors><pubmed_authors>Sinclair G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia.</name><description>Newborn screening for Cystic Fibrosis has been implemented in most programs worldwide, but the approach used varies, including combinations of immunoreactive trypsinogen (IRT) and CFTR mutation analysis on one or more specimens. The British Columbia (BC) newborn screening program tests ~45,000 infants per year in BC and the Yukon Territory, covering almost 1.5 million km&lt;sup>2&lt;/sup> in western Canada. CF screening was initiated using an IRT-DNA-IRT approach with a second bloodspot card at 21 days of age for all CFTR mutation heterozygotes and any non-carriers in the top 0.1% for IRT. This second IRT was implemented to avoid sweat testing of infants without persistent hypertrypsinemia, reducing the burden of travel for families. Over nine years (2010-2018), 401,977 infants were screened and</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jun</publication><modification>2025-04-19T00:43:40.674Z</modification><creation>2020-10-29T10:46:30Z</creation></dates><accession>S-EPMC7423010</accession><cross_references><pubmed>33073036</pubmed><doi>10.3390/ijns6020046</doi></cross_references></HashMap>